

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 23-F-011**

Please note that we have provided this information for the period January to April 2023.

### **You asked:**

#### **A. How many patients have been treated with the following drugs in the past 4 months:**

- Erenumab (Aimovig) - any disease - 13
- Eptinezumab (Vyepi) - any disease - 0
- Fremanezumab (Ajovy) - any disease - 95
- Galcanezumab (Emgality) - any disease - 22
- Rimegepant (Vydura) - any disease - 0
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY – 0

#### **B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:**

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Erenumab	14	0
Eptinezumab	0	0
Fremanezumab	108	0
Galcanezumab	20	<5*
Rimegepant	0	0
Botulinum Toxin	246	0

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as



unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

---

